GONADOTROPIN-RELEASING HORMONE RECEPTOR

Approval Year

Substance Class	Protein Created by `admin` on `Tue Apr 01 18:39:31 GMT 2025` Edited by `admin` on `Tue Apr 01 18:39:31 GMT 2025`
Protein Type	RECEPTOR
Protein Sub Type
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	MJK4KMT12V
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

GNRH RECEPTOR

Preferred Name

English

GONADOTROPIN-RELEASING HORMONE RECEPTOR

Common Name

English

GRHR

Common Name

English

Code System Code Type Description

FDA UNII

MJK4KMT12V

Created by admin on Tue Apr 01 18:39:31 GMT 2025 , Edited by admin on Tue Apr 01 18:39:31 GMT 2025

PRIMARY

From	To
1_114	1_196

Glycosylation Type

HUMAN

Glycosylation Link Type	Site
N	1_18
N	1_102

Related Record Type Details


					EFY6W0M8TG

LEUPROLIDE

AGONIST -> TARGET

Amount:


					OON1HFZ4BA

CETRORELIX

INHIBITOR -> TARGET

Amount:


					H50H3S3W74

HISTRELIN

AGONIST -> TARGET

Amount:


					56S17Z6X9M

SUFUGOLIX

INHIBITOR -> TARGET

Comments:

BINDING

Interaction Type:

NON-COMPETITIVE

Qualification:

IC50

Amount:


					W486SJ5824

ABARELIX

INHIBITOR -> TARGET


					P76B05O5V6

Relugolix

INHIBITOR -> TARGET

Amount:


					UJ8NQ5Z0VX

PEFORELIN

AGONIST -> TARGET

Amount:


					Q1IF8M2YL3

OZARELIX

INHIBITOR -> TARGET

Amount:


					2N7D33X56N

AZAGLY-NAFARELIN

AGONIST -> TARGET

Amount:


					PXW8U3YXDV

BUSERELIN

AGONIST -> TARGET

Amount:


					9081Y98W2V

TRIPTORELIN

AGONIST -> TARGET

Amount:


					66VRX9TN9T

BAY-1214784

INHIBITOR -> TARGET

Amount:


					9O7312W37G

GONADORELIN

AGONIST -> TARGET

Amount:


					7981LI6QXL

RAMORELIX

INHIBITOR -> TARGET

Amount:


					7CDW97HUEX

LINZAGOLIX

INHIBITOR -> TARGET

Amount:


					TKG3I66TVE

DESLORELIN

AGONIST -> TARGET

Amount:


					1X0094V6JV

NAFARELIN

AGONIST -> TARGET

Amount:


					IX503L9WN0

GANIRELIX

INHIBITOR -> TARGET

Amount:


					0F65R8P09N

GOSERELIN

AGONIST -> TARGET

Amount:


					Q041AO6T91

FERTIRELIN

AGONIST -> TARGET

Amount:


					05ME7P8ZBJ

DETIRELIX

INHIBITOR -> TARGET

Amount:


					D19V7048JK

TEVERELIX

INHIBITOR -> TARGET

Amount:


					68HX54O1VL

PRAZARELIX

INHIBITOR -> TARGET

Amount:


					VQ6CK0CITA

OPIGOLIX

INHIBITOR -> TARGET

Amount:


					SX0XJI3A11

DEGARELIX

INHIBITOR -> TARGET

Amount:


					ZD8NZ8J5LN

LECIRELIN

AGONIST -> TARGET

Comments:

Agonists do not quickly dissociate from the GnRH receptor. As a result, initially there is an increase in FSH and LH secretion (so-called "flare effect"). Levels of LH may increase by up to 10-fold,[15][16] while levels of testosterone generally increase to 140 to 200% of baseline values. However, after continuous administration, a profound hypogonadal effect (i.e. decrease in FSH and LH) is achieved through receptor downregulation by internalization of receptors. Generally this induced and reversible hypogonadism is the therapeutic goal.

Amount:


					94055UOQ3Y

ITURELIX

INHIBITOR -> TARGET

Amount:


					5B2546MB5Z

ELAGOLIX

INHIBITOR -> TARGET

Qualification:

IC50

Amount:

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT	CHEMICAL
Molecular Formula	CHEMICAL